ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1497

Endosomal TLR Triggering Of B Cells In Sjögren’s Syndrome Induces Increased Plasma Cells Differentiation, Ig Class Switch and Immunoglobulin Production

Marie Wahren-Herlenius1, Susanna Brauner1, Marika Kvarnström1, Lasse Folkersen1, Sabrina Görgen1, Christina Trollmo2, Vivianne Malmström3 and Gunnel Nordmark4, 1Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Medicine, Karolinska Institutet, Stochkolm, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: plasma cells and toll-like receptors, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Sjögren's Syndrome: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with primary Sjögren’s syndrome have B cell disturbances resulting in hypergammaglobulinemia and autoantibody production. Most patients are not treated by immunomodulatory drugs, enabling studies of an unmanipulated human autoreactive immune system. In this study we used the novel approach of employing vaccination as a tool to analyze immune responses in vivo. 

Methods:  Patients with Sjögren’s syndrome receiving no treatment and healthy controls were vaccinated twice against the H1N1 influenza, and monitored by multiple sampling. 

Results: Surprisingly, patients developed higher titers of IgG H1N1 antibodies, increased total IgG and increased autoantibody levels in response to vaccination. In addition, an expansion of CD138+ plasmablasts was observed, and up-regulation of several B cell promoting cytokines, including IL-10, IL-6 and IL-7. To dissect the B cell hyperreactivity, immunoglobulin class switch was induced in vitro in CD19+IgD+ B cells from patients and controls. Significantly more plasmablasts and higher titers of IgM and IgG were observed in TLR9 stimulated Sjögren-patient derived cultures in vitro. Similar results were obtained by TLR7 stimulation, but not by a-CD40 or BAFF that induce class switch through other pathways. The importance of the endosomal TLR pathway in plasma cell differentiation and immunoglobulin production was further demonstrated by analyzing B cells from patients treated with the drug chloroquine, which targets the endosome. In these patients, no differences were observed in class switch and plasma cell differentiation compared to healthy individuals. This observation was further confirmed by in vitro treatment of IgD+ B cells with chloroquine which significantly inhibited class switch and plasma cell differentiation. 

Conclusion: In conclusion, we demonstrate for the first time that B cell activation via endosomal TLRs leads to enhanced plasma cell differentiation and class-switch in patients with Sjögren’s syndrome, explaining the induction of hypergammaglobulinemia in Sjögren’s syndrome patients.


Disclosure:

M. Wahren-Herlenius,
None;

S. Brauner,
None;

M. Kvarnström,
None;

L. Folkersen,
None;

S. Görgen,
None;

C. Trollmo,
None;

V. Malmström,
None;

G. Nordmark,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endosomal-tlr-triggering-of-b-cells-in-sjogrens-syndrome-induces-increased-plasma-cells-differentiation-ig-class-switch-and-immunoglobulin-production/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology